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Background
Since the advent of antiretroviral (ARV) therapy for human 
immunodeficiency virus (HIV), treatment regimens have 
changed from complex, burdensome regimens to one pill 
once daily. Fixed-dose combination (FDC) pills for HIV are 
readily available and frequently used. Of the recommended 
initial regimens in the US Department of Health and Human 
Services’ (DHHS) treatment guidelines from October 2018, 
five are available as single-tablet regimens (STR).1
The importance of adherence to ARV therapy has been 
well-described, with poor adherence being associated with 
virologic failure and subsequent disease progression.2–6 
Multiple studies have shown that adherence to ARV therapy is 
improved by switching to a regimen with lower pill burden.7–12 
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Abstract
Background: Single-tablet regimens are preferred prescription choices for HIV treatment, but there are limited outcomes 
data comparing single-tablet regimens to multiple-tablet regimens.
Methods: We retrospectively assessed treatment-naïve patients at a single urban HIV clinic in the United States for viral 
load suppression at 6 and 12 months after initiating either single-tablet or multiple-tablet regimens. Multivariate regression 
was performed to obtain relative risks and adjust for potential confounders.
Results: Of 218 patients, 47% were on single-tablet regimens and 53% on multiple-tablet regimens; 77% of single-tablet 
regimen patients had undetectable viral load at 6 months compared to 61% of multiple-tablet regimen patients (p = 0.012). 
At 12 months, 82% on single-tablet regimens and 66% on multiple-tablet regimens (p = 0.019) had undetectable viral load. 
Relative risk of any detectable viral load was 1.6 (95% confidence interval: 1.1–2.5) for patients on multiple-tablet regimens 
compared to single-tablet regimens at 6 months, and 2.2 (95% confidence interval: 1.2–4.0) at 12 months.
Conclusion: Single-tablet regimens may provide better virologic control than multiple-tablet regimens in urban HIV-infected 
persons.
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A meta-analysis by Nachega et al.13 of twice-daily versus 
once-daily dosing across all regimens showed an improve-
ment of both adherence and virologic suppression with 
decrease in pill burden, but this was modest at best, and most 
commonly seen in treatment-naïve patients. While the above 
studies have investigated the effects of once-daily dosing and 
pill burden, none have directly assessed the use of STR.
Several observational studies have evaluated the effect of 
STR on factors such as adherence, patient satisfaction, hospi-
talization risks, and costs with mixed results.9,14–19 Both Sax 
et al.18 and Cohen et al.16 showed improvement in hospitaliza-
tion rates among patients using STR compared to multiple-
tablet regimens (MTR). Bangsberg et al.14 showed 
improvements in both adherence and virologic suppression in a 
population of marginally housed and homeless persons in San 
Francisco. Altogether, however, relatively few studies have 
assessed the impact of STR specifically compared to MTR for 
the outcome of virologic failure in a clinic population.
Understanding the impact of STR is especially important 
today, as we stand on the verge of multiple effective agents 
being available as generic formulations with the potential to 
decrease the cost of ARV therapy, and affect significant cost-
savings nationally, as shown by Walensky et al.20 in 2013. 
These cost-savings may result in a “desimplification” of 
treatment as patients on currently branded STR may be asked 
to change to a less costly multiple-pill alternative. The 
impact of such a proposed switch toward higher pill burden 
on adherence and outcome, especially in vulnerable popula-
tions, needs to be assessed.
We assessed virologic suppression at 6 and 12 months 
among urban ARV therapy-naïve patients starting their first 
regimen and compared virologic and immunologic outcomes 
of patients on STR with those on MTR.
Methods
Study design and setting
This is a retrospective cohort study. Patients were enrolled in 
the Infectious Disease Practice (IDP) at the New Jersey 
Medical School in Newark, NJ. Of the patients seen at this 
practice from 2007–2013, 46% were enrolled in Medicaid, 
25% self-pay or in hospital-based charity care, 22% in 
Medicare, and 7% with commercial insurance.
Study participants
After institutional internal review board approval, electronic 
medical records of new patients presenting for HIV care at the 
Infectious Diseases Practice between 2006 and 2013 were 
evaluated. Patients selected for study inclusion were ⩾18 years 
at initial visit, diagnosed as HIV-1 seropositive with a positive 
secondary laboratory conformation in the form of an Enzyme-
Linked Immunosorbent Assay (ELISA)/Western Blot, or an 
HIV-1 Ribonucleic Acid (RNA) Polymerase Chain Reaction 
(PCR) (“viral load”), previously never on ARV therapy, had a 
CD4+ T-lymphocyte count and HIV RNA viral load in their 
medical record before initiation of ARV therapy (“baseline”), 
and at least one additional CD4 count and viral load at least 
6 months after initiation of ARV therapy. Furthermore, eligible 
patients were subsequently started on STR or MTR as chosen 
by their provider, and continued on an uninterrupted and 
unchanged (as noted by the physician in the medical record) 
ARV regimen for a minimum of 6 months; patients switching 
therapy after 6 months were included in the study; however, 
12-month data were censored.
Patient data were excluded if the patient did not complete 
6 months of uninterrupted or unchanged ARV regimen. We 
defined an “interrupted” ARV regimen as a physician direc-
tive to stop taking medication. Patients were also excluded if 
baseline or 6-months post–ARV initiation CD4 count and 
viral load laboratory values were not present in the medical 
record.
ARV regimens
STR acceptable for inclusion consisted of the following 
three FDC pills: (1) emtricitabine, rilpivirine, and tenofovir 
disoproxil fumarate (TDF) (brand name Complera®); (2) 
efavirenz, emtricitabine, and TDF (brand name Atripla®), or 
(3) elvitegravir, cobicistat, emtricitabine, and TDF (brand 
name Stribild®), taken as one tablet once daily.
MTR acceptable for inclusion consisted of a nucleoside/
nucleotide reverse transcriptase inhibitor, non-nucleoside/
nucleotide reverse transcriptase inhibitor, protease inhibitor 
(PI), entry inhibitor, integrase inhibitor, or chemokine recep-
tor 5 antagonist taken in any formulation of two or more tab-
lets or capsules daily.
Data collection
Two study staff reviewed the medical record of every HIV-
infected patient newly presenting to the IDP between 2006 and 
2013. Data collected were age, gender, ethnicity, specific ARV 
medication regimen, date of ARV initiation, as well as baseline, 
6 month, 12 month, and most recent (at time of data collection) 
HIV viral load and CD4 count. The nearest value, in time, to 
the 6- or 12-month point was recorded for each patient. Current 
or past history of any treated or untreated mental illness, includ-
ing depression, schizophrenia, bipolar disorder, and anxiety, as 
evidenced by either a formally listed diagnosis with ICD-9 
(International Classification of Diseases) coding or a mention 
in the narrative of a physician’s note was recorded. These same 
criteria were used to determine inclusion of current or past sub-
stance use in study data; substances included were cocaine, 
heroin, methamphetamine, phencyclidine, MDMA, lysergic 
acid diethylamide, marijuana, and excessive alcohol use. 
Moderate or minimal alcohol use without dependence (as 
determined at the discretion of study staff because of variable 
phrasing in physicians’ notes) was excluded.
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Outcomes
Primary outcome was defined as HIV viral load below the 
limit of quantification (“undetectable”) of the specific sen-
sitivity of the PCR utilized in analyzing each unique blood 
sample 6 months after initiation of first ARV regimen. For 
the majority of patients seen prior to 2012, the lower limit 
of quantification was <48 copies/mL. For the majority of 
patients seen after 2012, the lower limit of quantification 
was <20 copies/mL. Secondary outcomes were viral load 
12 months after initiation of first ARV regimen, and CD4 
counts 6 and 12 months after initiation.
Data analysis
Statistical analyses were performed using SAS software 
(SAS Institute, Cary, NC). Baseline characteristics were 
considered at the medical visit at which ARV therapy was 
started. The Wilcoxon rank-sum test or the t-test were 
used to analyze differences in continuous variables. 
Pearson chi-square analysis was used for categorical vari-
ables. Differences between treatment groups in primary 
and secondary outcome measures at 6 and 12 months were 
performed using Pearson chi-square tests for viral load 
detectability (yes vs no) and the Wilcoxon rank-sum test 
for median CD4 count and CD4 count change. Multivariate 
log binomial regression analysis was performed to deter-
mine relative risks (RRs) for two models: (1) all patients, 
controlling for age, gender, mental illness, substance use 
disorder, and baseline viral load, and (2) for Black and 
Hispanic patients only, controlling for age, gender, mental 
illness, substance use disorder, baseline viral load, and 
race/ethnicity. The second model was performed to allow 
adjustment for race/ethnicity, which was not included in 




A total of 218 patients met the inclusion criteria. Of these, 103 
(47%) were initiated on STR and 115 (53%) on MTR. Table 1 
shows the differences in the baseline characteristics between 
the two groups. Patients in the STR group were less likely to 
be female (25% vs 44%, p < 0.005) and less likely to be Black 
(54% vs 70%, p = 0.025). A higher proportion of patients in the 
MTR group had a reported history of substance abuse: 53% 
compared to 39% in the STR group (p = 0.051).
Baseline virologic characteristics were similar between the 
two groups. Median HIV viral load for each group was compa-
rable. The MTR group had a lower median CD4 count of 226 
cells/mm3 as compared to 281 cells/mm3 in the STR group, but 
the difference was not statistically significant (p = 0.069).
Of the 103 patients on STR, 93 (91%) were on a FDC of 
efavirenz, TDF, and emtricitabine. Three patients (3%) were 
on a FDC of elvitegravir, cobicistat, TDF, and emtricitabine; 
and 7 (6%) on a FDC of rilpivirine, TDF, and emtricitabine.
The MTR regimens were more diverse: All patients were 
treated with a dual-nucleoside backbone. Forty-five patients 
(39%) were on boosted atazanavir, 34 (29%) on boosted daru-
navir, 22 patients (19%) on raltegravir, 9 (8%) on boosted 
fosamprenavir, 4 (3%) on boosted lopinavir, and 1 (<1%) on 
neviripine. Of the nucleoside backbones, 105 (91%) were 
TDF with emtricitabine, 7 (6%) were abacavir with lamivu-
dine, and 3 (3%) were zidovudine with lamivudine (Figure 1).
Virologic and immunologic outcomes
Data were available for all 218 patients at the 6-month fol-
low-up. The median time to follow-up was 182 days. Data 
were available for 169 patients at the 12-month follow-up. 
The median time to follow-up for this group was 364 days.
Table 1. Baseline characteristics of study population by treatment regimen.
Characteristic All patients 
(n = 218)
Single-tablet 
regimens (n = 103)
Multiple-tablet 
regimens (n = 115)
P-valuea
Mean age, years (SD) 43.58 (11.50) 42.11 (12.25) 44.90 (10.66) 0.074
Female (%) 77 (35.32%) 26 (25.24%) 51 (44.35%) 0.003
Race/ethnicity 0.025
 # Black (%) 136 (62.39%) 56 (54.37%) 80 (69.57%)  
 # Hispanic (%) 45 (20.64%) 29 (28.16%) 16 (13.91%)  
 # Other (%) 37 (16.97%) 18 (17.48%) 19 (16.52%)  
History of substance abuse 102 (46.79%) 41 (39.81%) 51 (53.04%) 0.051
History of mental illness 61 (27.98%) 25 (24.27%) 36 (31.30%) 0.248
Median HIV-1 viral load, copies/
mL (IQR)
42,705.50 (147,500) 45,679.00 (120,232) 35,900.00 (151,529) 0.714
Median CD4 count, mm3 (IQR) 233.50 (261) 281.00 (290) 226.00 (249) 0.069
SD, standard deviation; IQR, interquartile range.
aThe Wilcoxon rank-sum test or the t-test (for age) assessed group differences in continuous variable. The Pearson chi-square test assessed group differ-
ences in categorical variables.
Bold value represents an alpha of 0.05.
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Outcomes are shown in Table 2. Of patients on STR, 77% 
had an undetectable HIV viral load at 6 months compared to 
61% of patients on MTR (p = 0.012). These numbers 
improved at 12 months to 82% on STR arm and 66% on 
MTR arm (p = 0.019), but the STR continued to show statis-
tically significant higher rates of HIV virologic suppression 
compared to the MTR arm. At 6 months, the STR group had 
a significantly greater CD4 cell increase; however, CD4 
count increases at 12 months were similar.
We also looked for differences in HIV virologic outcomes 
among specific subpopulations (Table 3). Both men and 
women in the STR group had higher rates of virologic sup-
pression compared to their counterparts in the MTR group; 
however, statistical significance was only seen for men at the 
6-month time point, perhaps because of lower numbers of 
women at both time points and men at the 12-month time 
point.
Regimen switching
Eleven patients of the 218 studied switched regimens 
between the 6-month and 12-month measurements. At the 
time of switch, 8 patients had a detectable viral load and 3 
had an undetectable viral load. Four patients switched from 
STR to MTR, of which 3 had a detectable viral load at the 
time of switch. Two patients switched from one STR formu-
lation to another, both with an undetectable viral load at the 
time of switch. Four patients switched from one MTR to 
another, and 1 from MTR to STR and all of these had detect-
able viral loads at the time of switch.
Multivariate regression
Multivariate log binomial regression analysis to obtain RRs 
was performed controlling for demographic variables, base-
line viral load, and history of substance abuse or mental ill-
ness as documented at the start of the study (Model A in 
Table 4). RR of virologic failure defined as any detectable 
viral load at 6 months was 1.6 (95% confidence interval (CI): 
1.1–2.5) for patients on MTR compared to STR. At 
12 months, RR of failure (MTR compared with STR) was 2.2 
(95% CI: 1.2–4.0). Substance abuse, mental illness, gender, 
and age at enrollment were not found to be significant 
variables.
Regression analysis showed a similar effect when assess-
ing only Black and Hispanic patients, who accounted for 
most of the study population, controlling for above variables 
(Model B in Table 4). RR of failure on MTR compared to 
STR was 1.8 (95% CI: 1.1–2.9) at 6 months and 2.2 (95% CI: 
1.2–4.3) at 12 months.
Discussion
In this retrospective analysis of 218 treatment-naïve HIV 
infected persons in an urban US population, we found that 
initiation and maintenance of STR were associated with a 
significantly increased probability of undetectable HIV viral 
load at both 6 months and 12 months after initiation of ther-
apy. This effect remained significant even when controlling 
for baseline viral load as well as age, gender, self-identified 
race and ethnicity, and the presence of comorbid psychiatric 
illness or substance use disorder. In fact, at 12 months after 
controlling for the above variables, the RR of virologic fail-
ure was over twice as high for patients on an MTR compared 
to those on an STR.
Rates of virologic suppression in the STR arm of our 
study were 82% at one year. This success rate is comparable 
Figure 1. Multiple-tablet regimen components.
Atazanavir, darunavir, fosamprenavir, and lopinavir regimens included 
ritonavir for pharmacologic boosting. All regimens included dual nucleo-
side reverse transcriptase inhibitor backbone.
Table 2. Outcomes at 6 and 12 months by treatment group.














# undetectable VL (95% CI) 79 (77%) 70 (61%) 0.012 61 (82%) 63 (66%) 0.019
Median CD4 count, mm3 (IQR) 407 (332) 326 (319) 0.045 477 (339) 389 (309) 0.166
Median change in CD4, mm3 (IQR) +121 (124) +121 (172) 0.39 +180 (219) +165 (224) 0.52
VL, viral load; CI, confidence interval; IQR, interquartile range.
aUsing the Pearson chi-square test for undetectable VL and Wilcoxon rank-sum for median CD4 and change in CD4.
Bold value represents an alpha of 0.05.
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to 48-week virologic suppression rates in clinical trials of 
efavirenz combined with two nucleosides, which ranged 
from 78% to 94%.21–29 In contrast, the rate of virologic sup-
pression in the MTR arm, 66% at 12 months, are lower than 
that observed in clinical trials of raltegravir and ritonavir-
boosted darunavir, atazanavir, and lopinavir, which range 
from 76% for lopinavir to 86% for raltegravir.26–34 The dis-
crepancy between our results and clinical trial results, how-
ever, is likely related to different follow-up practices and 
monitoring in clinical trial populations, as well as our patient 
selection.
Meta-analyses by Nachega et al.13 and Clay et al.35 found 
consistent results of improved adherence and reduced risk 
of virologic failure in patients with STR. A meta-analysis by 
Van Galen et al.36 also suggested improved adherence 
though it did not assess the effect on virologic outcomes. 
Each of these analyses cited lack of randomized clinical tri-
als addressing the issue.
An observational study in a Veterans’ Administration 
cohort conducted by Sutton et al.37 found improvements in 
adherence rates resulted in a statistically significant odds ratio 
of 1.21 for undetectable viral load on follow-up analysis. Our 
study supports these findings in a younger population with 
high rates of poor insurance status. While our study was lim-
ited in the number of women enrolled, our results are consist-
ent with an analysis in the WIHS cohort conducted by Hanna 
et al.17 which found a modest improvement in virologic out-
comes in a time period associated with increased STR use.
Our results are most consistent with a prospective study by 
Bangsberg et al. in a cohort of homeless and marginally 
housed individuals in San Francisco that compared adherence 
and viral suppression between patients receiving an FDC of 
Table 3. Patients with undetectable VL at 6 and 12 months.














All patients (%) 79/103 (77%) 70/115 (61%) 0.012 61/74 (82%) 63/95 (66%) 0.019
Gender
 Men 60/77 (78%) 39/64 (61%) 0.028 45/56 (80%) 36/54 (67%) 0.104
 Women 19/26 (73%) 31/51 (61%) 0.286 16/18 (89%) 27/41 (66%) 0.06
Race/ethnicity
 Black 46/56 (82%) 49/80 (61%) 0.015 34/42 (81%) 44/65 (68%) 0.199
 Hispanic 21/29 (72%) 10/16 (63%) 0.262 18/21 (86%) 10/15 (67%) 0.171
 Other 12/18 (67%) 11/19 (58%) 0.842 9/11 (82%) 9/15 (60%) 0.226
Baseline CD4 (mm3)
 ⩽200 mm3 26/35 (74%) 28/49 (57%) 0.106 20/26 (77%) 23/39 (59%) 0.135
 >200 mm3 53/68 (78%) 42/66 (64%) 0.068 41/48 (85%) 40/56 (71%) 0.086
Baseline VL (copies/mL)
 ⩽100,000 copies/mL 57/70 (81%) 46/71 (65%) 0.026 39/47 (83%) 43/63 (68%) 0.079
 >100,000 copies/mL 22/33 (67%) 24/44 (55%) 0.284 22/27 (81%) 20/32 (63%) 0.109
VL, viral load.
aUsing the Pearson chi-square test for undetectable VL and Wilcoxon rank-sum for median CD4 and change in CD4. 
Bold value represents an alpha of 0.05.
Table 4. Relative risk of virologic failure, all patients.
Variable 6 months 6 months controlling 
for baseline VL
12 months 12 months controlling 
for baseline VL
Model A: All patients
 MTR vs STR 1.7 [1.1, 2.6] 1.6 [1.1, 2.5] 2.2 [1.2, 4.0] 2.2 [1.2, 4.0]
 Substance abuse 1.2 [0.8, 1.8] 1.1 [0.7, 1.9]  
 Mental illness 1.2 [0.7, 1.9] 0.8 [0.5, 1.3]  
 Female vs male 1.2 [0.8, 0.7] 1.0 [0.6, 1.7]  
 Age groups 0.8 [0.5, 1.5] 1.0 [0.5, 2.3]  
Model B: Black and Hispanic patients only
 MTR vs STR 1.8 [1.1, 2.6] 1.8 [1.1, 2.9] 2.1 [1.1, 4.0] 2.2 [1.2, 4.3]
VL, viral load; STR, single-tablet regimens; MTR, multiple-tablet regimens.
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efavirenz, TDF, and emtricitabine to those receiving MTR 
including non-nucleoside reverse transcriptase inhibitor and 
boosted PI containing regimens. They found that adherence 
was improved in the STR group compared to either of the 
MTR groups. Furthermore, the proportion of individuals with 
HIV viral loads <50 at 6 months was higher in the STR group 
than the MTR group (69% compared to 46%, p = 0.02).14
Conversely, Engsig et al. analyzed results of the Danish HIV 
Cohort Study during a period where all patients previously on 
an STR were instead switched to an MTR for cost-saving pur-
poses. This study found no significant difference in viral sup-
pression. Notably, this study excluded patients with anticipated 
problems with adherence as chosen by their physician. While 
adherence was not formally measured in the study, the exclu-
sion of patients at high risk of poor adherence may have blunted 
the potential benefit of a coformulated regimen.38
It is known that adherence to therapy can be an important 
marker of clinical indicators, including hospitalization, dis-
ease progression, virologic failure, and death.2–6 In prior stud-
ies, adherence has been shown to be improved in patients 
initiated on once-daily regimens and those with less pill-bur-
den, although not necessarily STR.9–19,35,36 Our study was not 
able to directly measure adherence to therapy, but we suspect 
the increase in adherence associated with a lower pill burden 
may have helped drive the outcomes found here, specifically 
virologic suppression. In addition, our study was limited to 
patients who tolerated their regimens for 6 months. Since 
intolerance is a common reason for switching from efavirenz, 
the primary STR used in this study, we were able to highlight 
the potential adherence effect of the pill formulation used, 
rather than adverse events related to the component drug.39
The need for information regarding the value of STR in 
HIV therapy is partially due to the anticipated arrival of 
entirely generic ARV regimens. The prospect of a generic 
regimen has important implications for cost-savings. An 
US-based estimate of cost savings calculated that a switch 
from branded therapy to generic therapy across the country 
would result in a $920 million dollar cost savings in the first 
year alone, or $42,500 per patient lifetime. When the same 
study considered decreased effectiveness of generic regi-
mens, the analysis suggested cost savings persisted; how-
ever, a potential loss of life expectancy was considered as a 
possible concomitant result.20 The overall threshold for cost-
effectiveness, however, is not likely to be interpreted equally 
among payer sources. One area for concern is that certain 
payers, including those that serve the most vulnerable popu-
lations, would be more inclined to accept cost-savings for a 
modest sacrifice in effectiveness. This is especially relevant 
to our practice population, as over two-thirds of patients seen 
in the practice during this study period were either enrolled 
in Medicaid, uninsured, or using hospital-based charity care. 
Over the past few months, we have heard anecdotes of sev-
eral patients forced by their insurance providers to switch 
from a STR regimen to a payer-preferred MTR regimen, 
despite viral suppression on the STR. The next few years 
may tell us if these switches will become more common and 
result in inferior virologic outcomes.
There are a number of limitations to this study. As a retro-
spective study, unmeasured confounders may exist that 
impact results: including insurance status, adherence, and 
provider beliefs about patients’ likely adherence. Sample 
size did not allow for between-regimen comparisons in sub-
groups, so this study cannot compare effectiveness among 
individual regimens. Nonetheless, clinical trial data and 
meta-analysis have demonstrated similar rates of viral load 
suppression for raltegravir, atazanavir, and darunavir—the 
main regimens in the MTR group—when compared to efa-
virenz.40 As a consequence of the study period, a majority of 
the patients on STR were placed on efavirenz/TDF/emtricit-
abine, and newer STR including dolutegravir/abacavir/lami-
vudine were not available for this study population. Perhaps 
because of the high use of efavirenz as an STR and the risk 
of teratogenic effects associated with this drug, fewer women 
are represented in the STR group overall. This likely no 
longer represents the trend, as STR without this drawback 
are readily available. Finally, information for patients with 
incomplete treatment before 6 months or loss-to-follow-up 
before that time was not available, and this may impact inter-
pretation of the results.
Providers’ perception of a patient’s potential adherence 
may have affected regimen choice. Emergent ARV resist-
ance is very uncommon with current boosted PI containing 
regimens, and with the integrase inhibitor dolutegravir, in 
contrast to the emergent resistance described among indi-
viduals failing efavirenz-containing regimens.29,41,42 
Therefore, clinicians may preferentially choose boosted-PI 
or integrase inhibitor containing regimens for patients deter-
mined to be high risk for medication nonadherence. While 
factors leading to treatment decision making could not be 
addressed directly in this study, we attempted to mitigate this 
by assessing impact of age, substance use disorder, and men-
tal illness (risk factors for non-adherence) on virologic sup-
pression. After controlling for these factors, the favorable 
effect on virologic suppression persisted in patients receiv-
ing STR. Additional unmeasured factors such as intended 
pregnancy, or drug interactions, may have impacted provider 
choice and are not accounted for in this analysis.
In summary, we found that daily STR had higher rates of 
undetectable viral load at 6 months and 12 months of therapy 
than MTR in a population of patients largely dependent on 
public assistance for ARV therapy. Generic MTR are 
expected to become available within the next few years, 
allowing a less costly treatment option for patients and pay-
ers. While the choice between cost and convenience remains 
complex, this study helps support the continued use of STR, 
especially in our most vulnerable populations.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest 
with respect to the research, authorship, and/or publication of this 
Kapadia et al. 7
article: S.S. has received grant support from Gilead Sciences and 
consulting fees from Viiv and Gilead Sciences. S.H. has received 
consulting fees from Bristol-Meyers Squibb, Gilead Sciences, 
Janssen Pharmaceuticals, and Viiv. Her spouse has received consult-
ing fees from Johnson and Johnson and Inovia, and retains stock 
options from Merck. 
Ethical approval
Ethical approval for this study was obtained from Rutgers New 
Jersey Medical School Institutional Review Board (Protocol 
Pro20120028).
Funding
The author(s) received no financial support for the research, author-
ship, and/or publication of this article.
Informed consent
Informed consent was not sought for the present study because it 
was a retrospective study of existing data and consent would not 
have been feasible.
ORCID iD
Shashi N Kapadia  https://orcid.org/0000-0001-6363-2839
References
 1. Panel on Antiretroviral Guidelines for Adults Adolescents. 
Guidelines for the use of antiretroviral agents in HIV-1 
infected adults and adolescents. Department of Health and 
Human Services, 2018, https://aidsinfo.nih.gov/contentfiles/
lvguidelines/adultandadolescentgl.pdf
 2. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence 
to highly active antiretroviral therapy predicts progression to 
AIDS. AIDS 2001; 15(9): 1181–1183.
 3. Fielden SJ, Rusch ML, Yip B, et al. Nonadherence increases 
the risk of hospitalization among HIV-infected antiretrovi-
ral naive patients started on HAART. J Int Assoc Physicians 
AIDS Care 2008; 7(5): 238–244.
 4. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-
based assessment of adherence to HAART predicts virologic 
and immunologic treatment response and clinical progression 
to AIDS and death. Int J STD AIDS 2004; 15(12): 803–810.
 5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease 
inhibitor therapy and outcomes in patients with HIV infection. 
Ann Intern Med 2000; 133(1): 21–30.
 6. Wood E, Hogg RS, Yip B, et al. Effect of medication adher-
ence on survival of HIV-infected adults who start highly 
active antiretroviral therapy when the CD4+ cell count is 
0.200 to 0.350 x 10(9) cells/L. Ann Intern Med 2003; 139(10): 
810–816.
 7. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day 
HAART: a simplification strategy that improves adherence 
and quality of life of HIV-infected subjects. Patient Prefer 
Adherence 2010; 4: 115–125.
 8. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification 
of antiretroviral therapy to a single-tablet regimen consisting 
of efavirenz, emtricitabine, and tenofovir disoproxil fuma-
rate versus unmodified antiretroviral therapy in virologically 
suppressed HIV-1-infected patients. J Acquir Immune Defic 
Syndr 2009; 51(2): 163–174.
 9. Hodder SL, Mounzer K, Dejesus E, et al. Patient-reported 
outcomes in virologically suppressed, HIV-1-infected sub-
jects after switching to a simplified, single-tablet regimen of 
efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care 
STDS 2010; 24(2): 87–96.
 10. Parienti JJ, Bangsberg DR, Verdon R, et al. Better adherence 
with once-daily antiretroviral regimens: a meta-analysis. Clin 
Infect Dis 2009; 48(4): 484–488.
 11. Juday T, Grimm K, Zoe-Powers A, et al. A retrospective study 
of HIV antiretroviral treatment persistence in a commercially 
insured population in the United States. AIDS Care 2011; 
23(9): 1154–1162.
 12. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence 
rates favor different virologic outcomes for patients treated 
with nonnucleoside analogues or protease inhibitors. Clin 
Infect Dis 2005; 40(1): 158–163.
 13. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill bur-
den and once-daily antiretroviral treatment regimens for HIV 
infection: a meta-analysis of randomized controlled trials. Clin 
Infect Dis 2014; 58(9): 1297–1307.
 14. Bangsberg DR, Ragland K, Monk A, et al. A single tablet regi-
men is associated with higher adherence and viral suppression 
than multiple tablet regimens in HIV+ homeless and margin-
ally housed people. AIDS 2010; 24(18): 2835–2840.
 15. Buscher A, Hartman C, Kallen MA, et al. Impact of antiret-
roviral dosing frequency and pill burden on adherence among 
newly diagnosed, antiretroviral-naive HIV patients. Int J STD 
AIDS 2012; 23(5): 351–355.
 16. Cohen CJ, Meyers JL and Davis KL. Association between 
daily antiretroviral pill burden and treatment adherence, hos-
pitalisation risk, and other healthcare utilisation and costs in 
a US medicaid population with HIV. BMJ Open 2013; 3(8): 
e003028.
 17. Hanna DB, Hessol NA, Golub ET, et al. Increase in single-
tablet regimen use and associated improvements in adherence-
related outcomes in HIV-infected women. J Acquir Immune 
Defic Syndr 2014; 65(5): 587–596.
 18. Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiret-
roviral treatment and correlation with risk of hospitalization 
among commercially insured HIV patients in the United 
States. PLoS ONE 2012; 7(2): e31591.
 19. Chen Y, Chen K and Kalichman SC. Barriers to HIV medica-
tion adherence as a function of regimen simplification. Ann 
Behav Med 2017; 51: 67–78.
 20. Walensky RP, Sax PE, Nakamura YM, et al. Economic sav-
ings versus health losses: the cost-effectiveness of generic 
antiretroviral therapy in the United States. Ann Intern Med 
2013; 158(2): 84–92.
 21. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, 
cobicistat, emtricitabine, and tenofovir versus co-formulated efa-
virenz, emtricitabine, and tenofovir for initial treatment of HIV-1 
infection: a randomised, double-blind, phase 3 trial, analysis of 
results after 48 weeks. Lancet 2012; 379(9835): 2439–2448.
 22. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus 
efavirenz with tenofovir and emtricitabine in treatment-naive 
adults infected with HIV-1 (ECHO): a phase 3 randomised 
double-blind active-controlled trial. Lancet 2011; 378(9787): 
238–246.
8 SAGE Open Medicine
 23. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine 
versus efavirenz with two background nucleoside or nucleo-
tide reverse transcriptase inhibitors in treatment-naive adults 
infected with HIV-1 (THRIVE): a phase 3, randomised, non-
inferiority trial. Lancet 2011; 378(9787): 229–237.
 24. Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a 
randomized clinical trial of rilpivirine/emtricitabine/tenofovir 
disoproxil fumarate vs. AIDS 2014; 28(7): 989–997.
 25. ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus 
standard 600 mg dose in HIV-infected, antiretroviral-naive 
adults (ENCORE1): a randomised, double-blind, placebo-
controlled, non-inferiority trial. Lancet 2014; 383(9927): 
1474–1482.
 26. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy 
of raltegravir-based versus efavirenz-based combination ther-
apy in treatment-naive patients with HIV-1 infection: a multi-
centre, double-blind randomised controlled trial. Lancet 2009; 
374(9692): 796–806.
 27. Andersson LM, Vesterbacka J, Blaxhult A, et al. Lopinavir/
ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-
naive HIV-1-infected individuals over 144 weeks: an open-
label randomized controlled trial. Scand J Infect Dis 2013; 
45(7): 543–551.
 28. Honda M, Ishisaka M, Ishizuka N, et al. Open-label rand-
omized multicenter selection study of once daily antiretrovi-
ral treatment regimen comparing ritonavir-boosted atazanavir 
to efavirenz with fixed-dose abacavir and lamivudine. Intern 
Med 2011; 50(7): 699–705.
 29. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritona-
vir or efavirenz as part of a 3-drug regimen for initial treatment 
of HIV-1. Ann Intern Med 2011; 154(7): 445–456.
 30. Molina JM, Clotet B, vanLunzen J, et al. Once-daily dolute-
gravir is superior to once-daily darunavir/ritonavir in treat-
ment-naive HIV-1-positive individuals: 96 week results from 
FLAMINGO. J Int AIDS Soc 2014; 17(4 Suppl. 3): 190490.
 31. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus 
Efavirenz regimens in treatment-naive HIV-1-infected patients: 
96-week efficacy, durability, subgroup, safety, and metabolic 
analyses. J Acquir Immune Defic Syndr 2010; 55(1): 39–48.
 32. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-
daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, 
each in combination with tenofovir and emtricitabine, for 
management of antiretroviral-naive HIV-1-infected patients: 
48 week efficacy and safety results of the CASTLE study. 
Lancet 2008; 372(9639): 646–655.
 33. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of 
once-daily darunavir/ritonavir versus lopinavir/ritonavir in 
treatment-naive HIV-1-infected patients at week 48. AIDS 
2008; 22(12): 1389–1397.
 34. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegra-
vir versus raltegravir in antiretroviral-naive adults with HIV-1 
infection: 48 week results from the randomised, double-blind, 
non-inferiority SPRING-2 study. Lancet 2013; 381(9868): 
735–743.
 35. Clay PG, Nag S, Graham CM, et al. Meta-analysis of stud-
ies comparing single and multi-tablet fixed dose combi-
nation HIV treatment regimens. Medicine 2015; 94(42): 
e1677.
 36. vanGalen KA, Nellen JF and Nieuwkerk PT. The effect on 
treatment adherence of administering drugs as fixed-dose 
combinations versus as separate pills: systematic review and 
meta-analysis. AIDS Res Treat 2014; 2014: 967073.
 37. Sutton SS, Hardin JW, Bramley TJ, et al. Single- versus multi-
ple-tablet HIV regimens: adherence and hospitalization risks. 
Am J Manag Care 2016; 22(4): 242–248.
 38. Engsig FN, Gerstoft J, Helleberg M, et al. Effectiveness of 
antiretroviral therapy in individuals who for economic reasons 
were switched from a once-daily single-tablet regimen to a tri-
ple-tablet regimen. J Acquir Immune Defic Syndr 2014; 66(4): 
407–413.
 39. Leutscher PD, Stecher C, Storgaard M, et al. Discontinuation 
of efavirenz therapy in HIV patients due to neuropsychiatric 
adverse effects. Scand J Infect Dis 2013; 45(8): 645–651.
 40. Kryst J, Kawalec P and Pilc A. Efavirenz-based regimens in 
antiretroviral-naive HIV-infected patients: a systematic review 
and meta-analysis of randomized controlled trials. PLoS ONE 
2015; 10(5): e0124279.
 41. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing 
regimens for initial treatment of HIV-1 infection. N Engl J 
Med 2008; 358(20): 2095–2106.
 42. Llibre JM, Pulido F, Garcia F, et al. Genetic barrier to resist-
ance for dolutegravir. AIDS Rev 2015; 17(1): 56–64.
